You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SKF 83566 hydrobromide
Biological Activity for SKF 83566 hydrobromide
SKF 83566 hydrobromide is a potent and selective D1-like dopamine receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 μM for D2). Also antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). Displays selective inhibition of adenylyl cyclase 2 (AC2); inactive against AC1 or AC5. Centrally active following systemic administration in vivo.
Compound Libraries for SKF 83566 hydrobromide
Technical Data for SKF 83566 hydrobromide
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SKF 83566 hydrobromide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.07||5 with gentle warming|
Preparing Stock Solutions for SKF 83566 hydrobromide
The following data is based on the product molecular weight 413.15. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.42 mL||12.1 mL||24.2 mL|
|5 mM||0.48 mL||2.42 mL||4.84 mL|
|10 mM||0.24 mL||1.21 mL||2.42 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
Product Datasheets for SKF 83566 hydrobromide
References for SKF 83566 hydrobromide
References are publications that support the biological activity of the product.
Fritts et al (1998) Locomotor stereotypy produced by dexbenzetimide and scopol. is reduced by SKF 83566, not sulpiride. Pharmacol.Biochem.Behav. 60 639 PMID: 9678647
Meyer et al (1993) Effects of DA D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol.Biochem.Behav. 44 429 PMID: 8446676
Ohlstein and Berkowitz (1985) SCH 23390 and SK&F 83566 are antagonists at vascular DA and serotonin receptors. Eur.J.Pharmacol. 108 205 PMID: 3884345
Conley et al (2013) Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J.Pharmacol.Exp.Ther. 347 276 PMID: 24008337
If you know of a relevant reference for SKF 83566 hydrobromide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SKF 83566 hydrobromide, SKF 83566 hydrobromide supplier, Potent, selective, D1-like, antagonists, Dopamine, Receptors, D5, dopaminergic, SKF83566, hydrobromide, D1, and, Adenylyl, Cyclase, 1586, Tocris Bioscience
10 Citations for SKF 83566 hydrobromide
Citations are publications that use Tocris products. Selected citations for SKF 83566 hydrobromide include:
Belinsky et al (2013) DA receptors in human embryonic stem cell neurodifferentiation. Stem Cells Dev 22 1522 PMID: 23286225
Liu et al (2008) Increased DA level enhances male-male courtship in Drosophila. World J Gastroenterol 28 5539 PMID: 18495888
Li et al (2017) DA-dependent effects on basal and glutamate stimulated network dynamics in cultured hippocampal neurons. J Neurochem 140 550 PMID: 27925199
Leng et al (2017) Activation of DRD5 inhibits tumor growth by autophagic cell death. Autophagy 13 1404 PMID: 28613975
Stramiello (2008) D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology 55 871 PMID: 18644393
Xing et al (2015) DA D1 receptor activation regulates the expression of the estrogen synthesis gene aromatase B in radial glial cells. Hum Mol Genet 9 310 PMID: 26388722
Cassar et al (2015) A DA receptor contributes to paraquat-induced neurotoxicity in Drosophila. Learn Mem 24 197 PMID: 25158689
Savalli et al (2015) Regionally selective requirement for D1/D5 DArgic neurotransmission in the medial prefrontal cortex in object-in-place associative recognition memory. J Neurosci 22 69 PMID: 25593292
Huang et al (2014) D1/D5 receptors and histone deacetylation mediate the Gateway Effect of LTP in hippocampal dentate gyrus. Learn Mem 21 153 PMID: 24549570
Billes et al (2012) Leptin reduces food intake via a DA D2 receptor-dependent mechanism. Mol Metab 1 86 PMID: 24024122
Do you know of a great paper that uses SKF 83566 hydrobromide from Tocris? Please let us know.
Reviews for SKF 83566 hydrobromide
There are currently no reviews for this product. Be the first to review SKF 83566 hydrobromide and earn rewards!
Have you used SKF 83566 hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.